No­var­tis teams up with Ox­ford re­searchers to crunch big da­ta in­to clin­i­cal in­sights

Since Vas Narasimhan’s Day 1 as CEO of No­var­tis, he has cham­pi­oned da­ta sci­ence and dig­i­tal tech­nolo­gies as a key pri­or­i­ty at the phar­ma gi­ant. Al­most a year in­to his tenure, in a re­cent con­ver­sa­tion with the tech VC firm An­dreessen Horowitz, he high­light­ed the abil­i­ties to an­a­lyze pathol­o­gy im­ages and cen­tral­ize clin­i­cal tri­al plan­ning as two promis­ing ap­pli­ca­tions of ma­chine learn­ing.

But, he ad­mit­ted, there are ar­eas where it’s “sim­ply not met up”:

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN